LU81562A1 - Derives de phenyl-1 piperazine - Google Patents

Derives de phenyl-1 piperazine Download PDF

Info

Publication number: LU81562A1
Authority: LU; Luxembourg
Prior art keywords: compounds; radical; phenyl; ethanol; alkyl
Prior art date: 1978-08-01

Application number

LU81562A

Other languages

English (en)

French (fr)

Inventor

P Manoury

H Najer

Original Assignee

Synthelabo

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-08-01

Filing date

1979-07-30

Publication date

1981-03-24

1978-08-01 Priority claimed from FR7822672A external-priority patent/FR2432515A1/fr

1978-11-23 Priority claimed from FR7833105A external-priority patent/FR2442234A2/fr

1979-07-30 Application filed by Synthelabo filed Critical Synthelabo

1981-03-24 Publication of LU81562A1 publication Critical patent/LU81562A1/fr

Links

GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical class C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title description 15
229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 56
150000001875 compounds Chemical class 0.000 claims description 35
239000002253 acid Substances 0.000 claims description 19
-1 3-methylthio-phenyl Chemical group 0.000 claims description 9
150000003839 salts Chemical class 0.000 claims description 9
125000004432 carbon atom Chemical group C* 0.000 claims description 5
150000007513 acids Chemical class 0.000 claims description 4
125000000217 alkyl group Chemical group 0.000 claims description 3
229910052736 halogen Inorganic materials 0.000 claims description 3
125000005843 halogen group Chemical group 0.000 claims description 3
125000005842 heteroatom Chemical group 0.000 claims description 2
125000000623 heterocyclic group Chemical group 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
239000004480 active ingredient Substances 0.000 claims 1
125000002490 anilino group Chemical class [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
125000004429 atom Chemical group 0.000 claims 1
229910052799 carbon Inorganic materials 0.000 claims 1
239000003814 drug Substances 0.000 claims 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
238000000034 method Methods 0.000 claims 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 11
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 11
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 10
238000010992 reflux Methods 0.000 description 10
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 9
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 9
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
239000000155 melt Substances 0.000 description 5
239000000203 mixture Substances 0.000 description 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
229910000029 sodium carbonate Inorganic materials 0.000 description 5
239000000243 solution Substances 0.000 description 5
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
229910052938 sodium sulfate Inorganic materials 0.000 description 4
235000011152 sodium sulphate Nutrition 0.000 description 4
239000002904 solvent Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
230000000202 analgesic effect Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000013078 crystal Substances 0.000 description 3
238000001914 filtration Methods 0.000 description 3
239000012074 organic phase Substances 0.000 description 3
235000009518 sodium iodide Nutrition 0.000 description 3
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
BDHJWDISJPMJHA-UHFFFAOYSA-N ClCC[ClH]CCCl Chemical compound ClCC[ClH]CCCl BDHJWDISJPMJHA-UHFFFAOYSA-N 0.000 description 2
OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
150000008064 anhydrides Chemical class 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
150000004820 halides Chemical class 0.000 description 2
230000036407 pain Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical class C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000007363 ring formation reaction Methods 0.000 description 2
QPILZZVXGUNELN-UHFFFAOYSA-M sodium;4-amino-5-hydroxynaphthalene-2,7-disulfonate;hydron Chemical compound [Na+].OS(=O)(=O)C1=CC(O)=C2C(N)=CC(S([O-])(=O)=O)=CC2=C1 QPILZZVXGUNELN-UHFFFAOYSA-M 0.000 description 2
239000000829 suppository Substances 0.000 description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
KDKGWGUUUVROTO-UHFFFAOYSA-N 1-hydroxypiperazine Chemical compound ON1CCNCC1 KDKGWGUUUVROTO-UHFFFAOYSA-N 0.000 description 1
HTGCVLNFLVVCST-UHFFFAOYSA-N 1-piperazin-1-ylethanol Chemical class CC(O)N1CCNCC1 HTGCVLNFLVVCST-UHFFFAOYSA-N 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
241000906446 Theraps Species 0.000 description 1
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
239000012346 acetyl chloride Substances 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
238000010908 decantation Methods 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
MSQACBWWAIBWIC-UHFFFAOYSA-N hydron;piperazine;chloride Chemical compound Cl.C1CNCCN1 MSQACBWWAIBWIC-UHFFFAOYSA-N 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
150000002513 isocyanates Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
230000008018 melting Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
239000004089 psychotropic agent Substances 0.000 description 1
230000000506 psychotropic effect Effects 0.000 description 1
230000000552 rheumatic effect Effects 0.000 description 1
125000002653 sulfanylmethyl group Chemical group [H]SC([H])([H])[*] 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
208000009935 visceral pain Diseases 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

LU81562A 1978-08-01 1979-07-30 Derives de phenyl-1 piperazine LU81562A1 (fr)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
FR7822672		1978-08-01
FR7822672A FR2432515A1 (fr)	1978-08-01	1978-08-01	Derives de phenyl-1 piperazine et leur application en therapeutique
FR7833105		1978-11-23
FR7833105A FR2442234A2 (fr)	1978-08-01	1978-11-23	Derives de phenyl-1 piperazine et leur application en therapeutique
FR7916029		1979-06-22
FR7916029A FR2459797A2 (fr)	1978-08-01	1979-06-22	Derives de phenyl-1 piperazine et leur application en therapeutique

Publications (1)

Publication Number	Publication Date
LU81562A1 true LU81562A1 (fr)	1981-03-24

Family

ID=27250847

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU81562A LU81562A1 (fr)	1978-08-01	1979-07-30	Derives de phenyl-1 piperazine

Country Status (18)

Country	Link
JP (1)	JPS5522690A (da)
AU (1)	AU4930979A (da)
BE (1)	BE877994A (da)
DE (1)	DE2930440A1 (da)
DK (1)	DK321479A (da)
ES (1)	ES483003A1 (da)
FI (1)	FI792401A7 (da)
FR (1)	FR2459797A2 (da)
GB (1)	GB2027703A (da)
GR (1)	GR69703B (da)
IL (1)	IL57920A0 (da)
IT (1)	IT1123497B (da)
LU (1)	LU81562A1 (da)
NL (1)	NL7905810A (da)
NO (1)	NO792502L (da)
NZ (1)	NZ191140A (da)
PT (1)	PT70007A (da)
SE (1)	SE7906507L (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2582288B1 (fr) *	1985-05-21	1987-08-07	Massonnet Henry	Poubelle compacteuse perfectionnee
SE9904724D0 (sv) *	1999-12-22	1999-12-22	Carlsson A Research Ab	New modulators of dopamine neurotransmission I
USRE46117E1 (en)	1999-12-22	2016-08-23	Teva Pharmaceuticals International Gmbh	Modulators of dopamine neurotransmission
SE9904723D0 (sv) *	1999-12-22	1999-12-22	Carlsson A Research Ab	New modulators of dopamine neurotransmission II
EP2204363A1 (en)	2004-06-08	2010-07-07	NSAB, Filial af NeuroSearch Sweden AB, Sverige	New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission
KR101245075B1 (ko)	2004-06-08	2013-03-18	엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게	도파민 신경전달의 모듈레이터로서 신 2기치환된페닐피페리딘/피페라진
US7851629B2 (en)	2004-06-08	2010-12-14	Nsab, Filial Af Neurosearch Sweden Ab, Sverige	Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
WO2006040155A1 (en)	2004-10-13	2006-04-20	Neurosearch Sweden Ab	Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
SE529246C2 (sv)	2005-10-13	2007-06-12	Neurosearch Sweden Ab	Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
TWI579272B (zh)	2011-12-08	2017-04-21	梯瓦製藥國際有限責任公司	普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH353743A (fr) *	1955-06-29	1961-04-30	Parke Davis & Co	Procédé de préparation de pipérazines
US2976290A (en) *	1959-04-24	1961-03-21	Parke Davis & Co	Piperazine derivatives and methods for their production
FR2224464A1 (en) *	1973-04-05	1974-10-31	Synthelabo	N-Phenyl-N'-beta-hydroxy-ethyl piperazines - as analgesic and anti-inflammatory agents

1979
- 1979-06-22 FR FR7916029A patent/FR2459797A2/fr active Granted
- 1979-07-26 DE DE19792930440 patent/DE2930440A1/de not_active Withdrawn
- 1979-07-27 IT IT24749/79A patent/IT1123497B/it active
- 1979-07-27 GB GB7926224A patent/GB2027703A/en not_active Withdrawn
- 1979-07-27 NZ NZ191140A patent/NZ191140A/xx unknown
- 1979-07-27 AU AU49309/79A patent/AU4930979A/en not_active Abandoned
- 1979-07-27 NL NL7905810A patent/NL7905810A/nl not_active Application Discontinuation
- 1979-07-30 IL IL57920A patent/IL57920A0/xx unknown
- 1979-07-30 DK DK321479A patent/DK321479A/da not_active Application Discontinuation
- 1979-07-30 LU LU81562A patent/LU81562A1/fr unknown
- 1979-07-30 NO NO792502A patent/NO792502L/no unknown
- 1979-07-31 SE SE7906507A patent/SE7906507L/xx not_active Application Discontinuation
- 1979-07-31 ES ES483003A patent/ES483003A1/es not_active Expired
- 1979-07-31 BE BE0/196538A patent/BE877994A/fr unknown
- 1979-07-31 JP JP9858679A patent/JPS5522690A/ja active Pending
- 1979-07-31 PT PT70007A patent/PT70007A/pt unknown
- 1979-08-01 FI FI792401A patent/FI792401A7/fi not_active Application Discontinuation
1980
- 1980-07-27 GR GR59710A patent/GR69703B/el unknown

Also Published As

Publication number	Publication date
IL57920A0 (en)	1979-11-30
PT70007A (fr)	1979-08-01
BE877994A (fr)	1980-01-31
NO792502L (no)	1980-02-04
FI792401A7 (fi)	1981-01-01
SE7906507L (sv)	1980-02-02
DE2930440A1 (de)	1980-02-28
AU4930979A (en)	1980-02-07
GR69703B (da)	1982-07-09
IT1123497B (it)	1986-04-30
FR2459797B2 (da)	1982-05-14
DK321479A (da)	1980-02-02
ES483003A1 (es)	1980-04-16
FR2459797A2 (fr)	1981-01-16
IT7924749A0 (it)	1979-07-27
GB2027703A (en)	1980-02-27
NZ191140A (en)	1981-01-23
NL7905810A (nl)	1980-02-05
JPS5522690A (en)	1980-02-18

Publication	Publication Date	Title
FR2500450A1 (fr)	1982-08-27	Nouveaux derives aminomethyl-5 oxazolidiniques, leur procede de preparation et leur application en therapeutique
HU192439B (en)	1987-06-29	Process for producing n,n'-piperazinyl- derivatives and pharmaceutical compositions containing them
LU81396A1 (fr)	1981-02-03	Derives de phenylpiperazine
FR2639044A1 (fr)	1990-05-18	Derives de la butynylamine
FR2548666A1 (fr)	1985-01-11	Nouveaux derives du nor-tropane et du granatane, leur procede de preparation et leur application en therapeutique
LU81562A1 (fr)	1981-03-24	Derives de phenyl-1 piperazine
EP0007824A1 (fr)	1980-02-06	Nouveaux dérivés de benzofuranne, leur procédé de préparation et composition thérapeutiqueles contenant.
EP0048705B1 (fr)	1984-07-11	Nouveaux acides 2-(4-(diphénylméthylène)-1-pipéridinyl)-acétiques et leurs amides, leurs procédés de préparation et compositions thérapeutiques
EP0002978B1 (fr)	1982-10-06	Dérivés de thiazolidinedione-2,4, leur préparation et leur application en thérapeutique
CA1088070A (fr)	1980-10-21	Procede de preparation de nouveaux derives de l'aminobenzocycloheptene
EP0301936B1 (fr)	1992-12-16	Dérivés de pipéridine, leur préparation et leur application en thérapeutique
CA1117944A (fr)	1982-02-09	Procedes de preparation de nouvelles piperazines disubstituees
FR2643634A1 (fr)	1990-08-31	Nouveaux derives benzoxazolinoniques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
FR2530632A1 (fr)	1984-01-27	Nouveaux derives substitues du 2,5-diamino 1,4-diazole, leurs procedes de preparation et les compositions pharmaceutiques en renfermant
CA1100968A (fr)	1981-05-12	Procedes de preparation de nouvelles piperazines disubstituees
FR2637596A1 (fr)	1990-04-13	Methyl-4 ((aryl-4 piperazinyl-1)-2 ethyl)-5 thiazole et ses derives, leur procede de preparation et les medicaments en contenant
EP0119107B1 (fr)	1986-10-01	Nouveaux dérivés du bicyclo(4.2.0)octatriène-1,3,5, leur préparation et leur application en thérapeutique
FR2547822A1 (fr)	1984-12-28	Acylpiperazinoquinazolines substituees utiles comme medicaments et procede pour leur preparation
CH634311A5 (fr)	1983-01-31	Derives du benzo(d)thiazole, leur procede de preparation et leurs applications en therapeutique.
CA2010529A1 (fr)	1990-08-22	Derives de la 1-arylsulfonyl 2-piperidinone, leur procede et les intermediaires de preparation, leur application comme medicaments et les compositions les renfermant
FR2560873A1 (fr)	1985-09-13	Medicaments a base de derives de la piperidine, nouveaux derives de la piperidine et leurs procedes de preparation
EP0687252A1 (fr)	1995-12-20	Derives de la phenoxy-2 ethylamine, leur preparation et leur application en therapeutique
FR2580648A1 (fr)	1986-10-24	Nouveaux derives du triazole, leur procede de preparation et les compositions pharmaceutiques les renfermant
EP0157762B1 (fr)	1990-08-08	Nouvelles piperidinoguanidines substituees, leur procede de preparation et les compositions pharmaceutiques en renfermant
EP0100257B1 (fr)	1988-02-24	Nouveaux dérivés aminoalkyl naphtaléniques, leurs sels d'addition d'acide et le procédé de préparation ainsi que l'application en thérapeutique de ces dérivés et sels